Proton beam cancer therapy 'effective with fewer side effects'

A cancer treatment at the centre of an NHS controversy in 2014 causes fewer side effects in children than conventional radiotherapy, according to new research. The study, published in The Lancet Oncology, suggests proton beam therapy is as effective as other treatments. Researchers looked at 59 patients aged between three and 21 from 2003 to…

Read More

Can We Truly "Cure" Cancer?

Monica Bertagnolli, WMIF co-chair, chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and chair of the Alliance for Clinical Trials in Oncology, a nationwide effort to test new therapies, speaks on Barack Obama’s aspirational plan in his final State of the Union to “cure cancer.”

Read More

Can We Truly "Cure" Cancer?

Monica Bertagnolli, WMIF co-chair, chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and chair of the Alliance for Clinical Trials in Oncology, a nationwide effort to test new therapies, speaks on Barack Obama’s aspirational plan in his final State of the Union to “cure cancer.”

Read More

Innovator Profile: Innovation's Building Blocks

A profile of Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM). Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM), is no stranger to the celebrity side of science. Coming of age…

Read More

Innovator Profile: Innovation's Building Blocks

A profile of Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM). Charles Serhan, PhD, DSc, a mastermind behind the inflammation pro-resolving therapies known as resolvins and the specialized pro-resolving mediators (SPM), is no stranger to the celebrity side of science. Coming of age…

Read More

Fierce 15: Two Partners Spinoffs Awarded Honors

Earlier this fall, Partners HealthCare spinoffs Editas Medicine and Spero received global recognition. Earlier this fall, Partners HealthCare spinoffs Editas Medicine and Spero received global recognition when they were named to the prestigious Fierce Biotech's Fierce 15, an annual compilation of leading biotech upstarts. Researchers around the globe are pursuing various strategies for correcting defective…

Read More

Fierce 15: Two Partners Spinoffs Awarded Honors

Earlier this fall, Partners HealthCare spinoffs Editas Medicine and Spero received global recognition. Earlier this fall, Partners HealthCare spinoffs Editas Medicine and Spero received global recognition when they were named to the prestigious Fierce Biotech's Fierce 15, an annual compilation of leading biotech upstarts. Researchers around the globe are pursuing various strategies for correcting defective…

Read More

CoStim's Novel Biologics Target Immune Checkpoint Inhibitors

Partners HealthCare spin-off, CoStim Pharmaceuticals, positioned to be a leader in the immune checkpoint regulation market. With excitement growing around immune checkpoint regulation as a major advance in treating cancer, the emergence of Partners HealthCare spin-off CoStim Pharmaceuticals could not be better timed. Industry experts expect the immune checkpoint therapy market will continue to grow…

Read More